Dr. Vinay Prasad had been serving as the FDA's director of the Center for Biologics Evaluation and Research since May, and ...

Dr. Vinay Prasad, the chief scientific officer at the Food and Drug Administration, has resigned after only three months in ...

WASHINGTON, DC – Dr. Vinay Prasad, the polarizing official who led U.S. vaccine oversight under the Trump administration, has ...

Vinay Prasad, who came under fire from patient advocacy groups and Laura Loomer, is gone after less than three months on the ...

After losing 3,500 employees in April—19% of its workforce due to congressional budget cuts—the FDA is now struggling to meet ...

A fter just a few controversial months, Vinay Prasad, MD, MPH, has stepped down as director of FDA's Center for Biologics Evaluation and Research (CBER).

Prasad’s short FDA tenure brought stricter review standards for gene and COVID vaccines, sparking biotech concern and political backlash.

Vinay Prasad, who headed the U.S. FDA division in charge of vaccines and was also chief medical and scientific officer, has ...

Vinay Prasad resigns from the FDA after backlash over vaccine restrictions and gene therapy decisions. Political pressure cited in sudden departure.

In this pilot episode of the Applied Clinical Trials Brief, we examine the renewed push for placebo-controlled vaccine trials ...

Shares of Novavax are trading lower Friday morning. The stock appears to be caught in a downdraft affecting COVID-19 vaccine ...

Novavax (NASDAQ: NVAX) ended its seventh consecutive session in the red territory after shares of the company declined 1.35% to close at $6.56 on Friday. The vaccine maker lost close to 13% in the ...